undamentalytics Newsletter
Sign in

Kiniksa Pharmaceuticals International, plc revenue

Kiniksa Pharmaceuticals International, plc's revenue was $678m in fiscal 2025, up 60.1% on the year before. Since fiscal 2021 ($38.5m) it has grown at a compound 104.8% a year. Over the last twelve months it was $946m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue39220270423678946
Growth on the year before—+471.2%+22.7%+56.6%+60.1%—
Gross profit29197237362600853
Gross margin76.4%89.6%87.6%85.6%88.5%90.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Kiniksa Pharmaceuticals International, plc $946m 58.2% 56.1%
Bridgebio Pharma, Inc. $946m 167.3% 364.6%
Biocryst Pharmaceuticals Inc $941m 68.7% 45.3%
Ionis Pharmaceuticals Inc $874m -7.4% 11.5%
Legend Biotech Corp $1.03bn 64.0% —
Ascendis Pharma A/s $814m 106.9% —

Compare with peers

Head to head: BBIO vs KNSABCRX vs KNSAIONS vs KNSAKNSA vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kiniksa Pharmaceuticals International, plc's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kiniksa Pharmaceuticals International, plc.